Last reviewed · How we verify
H02+CHOP
H02+CHOP is a chemotherapy combination regimen that uses doxorubicin, cyclophosphamide, vincristine, and prednisone to inhibit cancer cell proliferation and induce apoptosis.
H02+CHOP is a chemotherapy combination regimen that uses doxorubicin, cyclophosphamide, vincristine, and prednisone to inhibit cancer cell proliferation and induce apoptosis. Used for Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma based on CHOP standard use).
At a glance
| Generic name | H02+CHOP |
|---|---|
| Sponsor | Shandong New Time Pharmaceutical Co., LTD |
| Drug class | Polychemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CHOP is a standard polychemotherapy regimen where each agent targets different aspects of cancer cell survival: cyclophosphamide and doxorubicin cause DNA damage, vincristine disrupts microtubule formation to prevent mitosis, and prednisone provides immunosuppression and anti-inflammatory effects. The H02 component likely refers to an additional agent or modification, though the exact composition is not clearly defined in available literature.
Approved indications
- Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma based on CHOP standard use)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H02+CHOP CI brief — competitive landscape report
- H02+CHOP updates RSS · CI watch RSS
- Shandong New Time Pharmaceutical Co., LTD portfolio CI